ArticleFrontiers in cardiovascular medicine2026
SCAPIS 2 spectrum: rationale, objectives and design of a microvascular dysfunction sub-study within the Swedish CArdioPulmonary bioImage study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07359768 (SCAPIS 2 - Spectrum Study -CVD Risk Based on Microvascular Dysfunction), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SCAPIS 2 - Spectrum Study -CVD Risk Based on Microvascular Dysfunction
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microvasculature forms the interface for nutrient exchange and signaling between the blood and tissues. Its dysfunction is increasingly recognized as a key mechanism underlying various cardiovascular diseases, including heart failure, ischemic heart disease, atherosclerosis, stroke and vascular dementia. Early detection of these subclinical processes using non-invasive assessments could facilitate timely interventions and provide mechanistic insights to prevent disease progression. SCAPIS 2 Spectrum is a prospective cross-sectional phenotyping sub study of the Swedish Cardiopulmonary Bioimage Study, recruiting up to 900 participants aged 58-75 years. The study is organized into four overlapping phenotype groups: (1) those with obstructive coronary artery disease, (2) angina with non-obstructive coronary arteries, (3) metabolic syndrome with type 2 diabetes, and (4) those with diastolic dysfunction, each compared with controls drawn from the same cohort. All participants undergo a comprehensive skin microvascular assessment at rest and following various local provocations and those without exclusion criteria or obstructive coronary artery disease will also undergo stress cardiovascular magnetic resonance imaging to assess myocardial perfusion. Descriptive statistics, association analysis, multivariable regression and exploratory modelling will be employed to investigate associations between device-derived parameters in skin microcirculation and myocardial perfusion. Circulating biomarkers will be incorporated as candidate features in exploratory analysis. Ethical approval has been obtained from the Swedish Ethical Review Authority and the Swedish Medical Products Agency (CIV-ID 23-12-045355). Study results will be disseminated through peer-reviewed publications, national and international conference presentations. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT07359768?term=scapis%202%20spectrum&viewType=Card&rank=1&tab=study, ClinicalTrials.gov ID: NCT07359768.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.